» Articles » PMID: 17098740

Phylogenetic Divergence of CD47 Interactions with Human Signal Regulatory Protein Alpha Reveals Locus of Species Specificity. Implications for the Binding Site

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2006 Nov 14
PMID 17098740
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

Cell-cell interactions between ubiquitously expressed integrin-associated protein (CD47) and its counterreceptor signal regulatory protein (SIRPalpha) on phagocytes regulate a wide range of adhesive signaling processes, including the inhibition of phagocytosis as documented in mice. We show that CD47-SIRPalpha binding interactions are different between mice and humans, and we exploit phylogenetic divergence to identify the species-specific binding locus on the immunoglobulin domain of human CD47. All of the studies are conducted in the physiological context of membrane protein display on Chinese hamster ovary (CHO) cells. Novel quantitative flow cytometry analyses with CD47-green fluorescent protein and soluble human SIRPalpha as a probe show that neither human CD47 nor SIRPalpha requires glycosylation for interaction. Human CD47-expressing CHO cells spread rapidly on SIRPalpha-coated glass surfaces, correlating well with the spreading of primary human T cells. In contrast, CHO cells expressing mouse CD47 spread minimally and show equally weak binding to soluble human SIRPalpha. Further phylogenetic analyses and multisite substitutions of the CD47 Ig domain show that human to cow mutation of a cluster of seven residues on adjacent strands near the middle of the domain decreases the association constant for human SIRPalpha to about one-third that of human CD47. Direct tests of cell-cell adhesion between human monocytes and CD47-displaying CHO cells affirm the species specificity as well as the importance of the newly identified binding locus in cell-cell interactions.

Citing Articles

Post-translational modifications of immune checkpoints: unlocking new potentials in cancer immunotherapy.

Hu Q, Shi Y, Wang H, Bing L, Xu Z Exp Hematol Oncol. 2025; 14(1):37.

PMID: 40087690 DOI: 10.1186/s40164-025-00627-6.


The Physiological and Therapeutic Role of CD47 in Macrophage Function and Cancer.

Bess S, Igoe M, Muldoon T Immunol Invest. 2024; 54(1):112-146.

PMID: 39415597 PMC: 11774679. DOI: 10.1080/08820139.2024.2415409.


Structural-functional diversity of CD47 proteoforms.

Zhang T, Wang F, Xu L, Yang Y Front Immunol. 2024; 15:1329562.

PMID: 38426113 PMC: 10902115. DOI: 10.3389/fimmu.2024.1329562.


Suppressing or Enhancing Macrophage Engulfment through the Use of CD47 and Related Peptides.

Jalil A, Tobin M, Discher D Bioconjug Chem. 2022; 33(11):1989-1995.

PMID: 35316023 PMC: 9990087. DOI: 10.1021/acs.bioconjchem.2c00019.


Advances in culture methods for acute myeloid leukemia research.

Syama K, Hassan E, Zou S Oncoscience. 2021; 8:82-90.

PMID: 34368398 PMC: 8336936. DOI: 10.18632/oncoscience.540.